{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:38:19Z","timestamp":1771486699795,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s10549-023-06867-6","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T13:02:33Z","timestamp":1677934953000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: a multicenter retrospective case\u2013control study"],"prefix":"10.1007","volume":"199","author":[{"given":"Jui-Hung","family":"Tsai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung-Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dah-Cherng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Sheng","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Chiang","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9670-5571","authenticated-orcid":false,"given":"Chin-Yao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Lung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,4]]},"reference":[{"issue":"5","key":"6867_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/jco.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N (2008) Preoperative chemotherapy: updates of National surgical adjuvant breast and bowel project protocols B-18 and B-27. J clin oncol: off J American Soc Clin Oncol 26(5):778\u2013785. https:\/\/doi.org\/10.1200\/jco.2007.15.0235","journal-title":"J clin oncol: off J American Soc Clin Oncol"},{"key":"6867_CR2","unstructured":"1.2021) BCV. National Comprehensive Cancer Network, vol. 2021."},{"issue":"5","key":"6867_CR3","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1093\/annonc\/mdn728","volume":"20","author":"PJ Barrett-Lee","year":"2009","unstructured":"Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, Palmieri C, Plummer CJ, Stanley A, Verrill MW (2009) Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann oncol: off J European Soc Med Oncol 20(5):816\u2013827. https:\/\/doi.org\/10.1093\/annonc\/mdn728","journal-title":"Ann oncol: off J European Soc Med Oncol"},{"key":"6867_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","volume":"7","author":"D Cardinale","year":"2020","unstructured":"Cardinale D, Iacopo F, Cipolla CM (2020) Cardiotoxicity of anthracyclines. Front cardiovasc med 7:26. https:\/\/doi.org\/10.3389\/fcvm.2020.00026","journal-title":"Front cardiovasc med"},{"issue":"4","key":"6867_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.ejps.2011.09.006","volume":"45","author":"A Gabizon","year":"2012","unstructured":"Gabizon A, Shmeeda H, Grenader T (2012) Pharmacological basis of pegylated liposomal doxorubicin: impact on cancer therapy. European J Pharm sci: off J European Fed Pharm Sci 45(4):388\u2013398. https:\/\/doi.org\/10.1016\/j.ejps.2011.09.006","journal-title":"European J Pharm sci: off J European Fed Pharm Sci"},{"issue":"5","key":"6867_CR6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1081\/cnv-200032899","volume":"22","author":"AA Gabizon","year":"2004","unstructured":"Gabizon AA, Lyass O, Berry GJ, Wildgust M (2004) Cardiac safety of pegylated liposomal doxorubicin (Doxil\/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer investig 22(5):663\u20139. https:\/\/doi.org\/10.1081\/cnv-200032899","journal-title":"Cancer investig"},{"issue":"5","key":"6867_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharm 42(5):419\u201336. https:\/\/doi.org\/10.2165\/00003088-200342050-00002","journal-title":"Clin Pharm"},{"key":"6867_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","volume":"29","author":"AA Gabizon","year":"2016","unstructured":"Gabizon AA, Patil Y, La-Beck NM (2016) New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug res updat\u202f: rev comment antimicrob anticancer chemother 29:90\u2013106. https:\/\/doi.org\/10.1016\/j.drup.2016.10.003","journal-title":"Drug res updat : rev comment antimicrob anticancer chemother"},{"issue":"1","key":"6867_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41598-020-80415-w","volume":"11","author":"W Liu","year":"2021","unstructured":"Liu W, Chen W, Zhang X, Zhao P, Fan Z, Bi L, Wu D, Li S, Yang M, Fu T, Song D, Han B, Zhao G, Du Y, Shi A (2021) Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin. Sci rep 11(1):199. https:\/\/doi.org\/10.1038\/s41598-020-80415-w","journal-title":"Sci rep"},{"issue":"4","key":"6867_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/1120009x.2020.1746886","volume":"32","author":"J Yao","year":"2020","unstructured":"Yao J, Pan S, Fan X, Jiang X, Yang Y, Jin J, Liu Y (2020) Pegylated liposomal doxorubicin as neoadjuvant therapy for stage II-III locally advanced breast cancer. J chemother (Florence, Italy) 32(4):202\u201307. https:\/\/doi.org\/10.1080\/1120009x.2020.1746886","journal-title":"J chemother (Florence, Italy)"},{"key":"6867_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5729389","volume":"202","author":"CC Hung","year":"2020","unstructured":"Hung CC, Yang Y, Tsai IC, Hsu CY, Liu CH, Yang JR (2020) The efficacy of pegylated liposomal doxorubicin-based neoadjuvant chemotherapy in breast cancer: a retrospective case-control study in Taiwan. Biochem Res Int 202:1\u20139. https:\/\/doi.org\/10.1155\/2020\/5729389","journal-title":"Biochem Res Int"},{"key":"6867_CR12","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.2147\/ott.S162003","volume":"11","author":"M Dong","year":"2018","unstructured":"Dong M, Luo L, Ying X, Lu X, Shen J, Jiang Z, Wang L (2018) Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study. OncoTargets therapy 11:4247\u20134252. https:\/\/doi.org\/10.2147\/ott.S162003","journal-title":"OncoTargets therapy"},{"issue":"9938","key":"6867_CR13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/s0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (London, England) 384(9938):164\u201372. https:\/\/doi.org\/10.1016\/s0140-6736(13)62422-8","journal-title":"Lancet (London, England)"},{"issue":"5","key":"6867_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000498993","volume":"42","author":"M Cheng","year":"2019","unstructured":"Cheng M, Song Z, Qi Y, Wang X, Zhang L, Shi J, Wang M (2019) A dose-escalating pilot study (NCT03017404) of pegylated liposomal doxorubicin and cyclophosphamide, followed by docetaxel administration as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer. Oncol res treat 42(5):269\u201374. https:\/\/doi.org\/10.1159\/000498993","journal-title":"Oncol res treat"},{"issue":"1","key":"6867_CR15","doi-asserted-by":"publisher","first-page":"18135","DOI":"10.1038\/s41598-019-54387-5","volume":"9","author":"R Li","year":"2019","unstructured":"Li R, Tian F, Qi Y, Ma L, Zhou T, Li Y, Hui T, Zhang L, Wang S, Song Z (2019) Pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer (registration number: ChiCTR1900023052). Sci rep 9(1):18135. https:\/\/doi.org\/10.1038\/s41598-019-54387-5","journal-title":"Sci rep"},{"issue":"3","key":"6867_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10549-015-3415-2","volume":"151","author":"MJ Gil-Gil","year":"2015","unstructured":"Gil-Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesia C, Garcia-Mart\u00ednez E, Martinez-J\u00e1\u00f1ez N, Mel\u00e9 M, Llombart A, Pernas S, Villagrasa P, Blasco C, Baselga J (2015) Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast cancer res treat 151(3):597\u2013606. https:\/\/doi.org\/10.1007\/s10549-015-3415-2","journal-title":"Breast cancer res treat"},{"issue":"1","key":"6867_CR17","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1186\/s12885-021-09050-6","volume":"21","author":"J Zhang","year":"2021","unstructured":"Zhang J, Jiang H, Zhang J, Bao G, Zhang G, Wang H, Wang X (2021) Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study. BMC cancer 21(1):1301. https:\/\/doi.org\/10.1186\/s12885-021-09050-6","journal-title":"BMC cancer"},{"issue":"3","key":"6867_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O'Brien","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann oncol: off J European Soc Med Oncol 15(3):440\u2013449. https:\/\/doi.org\/10.1093\/annonc\/mdh097","journal-title":"Ann oncol: off J European Soc Med Oncol"},{"issue":"1","key":"6867_CR19","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.25011\/cim.v44i1.35196","volume":"44","author":"IC Tsai","year":"2021","unstructured":"Tsai IC, Hung CC (2021) Efficacy of pegylated liposomal doxorubicin-based neoadjuvant chemotherapy in breast cancer: a single center experience. Clin Investig Med Med Clin et Exp 44(1):E7-14","journal-title":"Clin Investig Med Med Clin et Exp"},{"issue":"12","key":"6867_CR20","first-page":"7319","volume":"34","author":"MY Lien","year":"2014","unstructured":"Lien MY, Liu LC, Wang HC, Yeh MH, Chen CJ, Yeh SP, Bai LY, Liao YM, Lin CY, Hsieh CY, Lin CC, Li LY, Lin PH, Chiu CF (2014) Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer. Anticancer Res 34(12):7319\u20137326","journal-title":"Anticancer Res"},{"issue":"8","key":"6867_CR21","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, K\u00fcmmel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A (2019) A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann oncol\u202f: off J European Soc Med Oncol 30(8):1279\u20131288. https:\/\/doi.org\/10.1093\/annonc\/mdz158","journal-title":"Ann oncol : off J European Soc Med Oncol"},{"key":"6867_CR22","doi-asserted-by":"publisher","first-page":"S1142","DOI":"10.1016\/annonc\/annonc325","volume":"31","author":"G Bianchini","year":"2020","unstructured":"Bianchini G, Huang C, Egle D, Bermejo B, Zamagni C, Thill M, Anton A, Zambelli S, Russo S, Ciruelos EM, Greil R, Semiglazov V, Colleoni MA, Kelly CM, Mariani G, Mastro LD, Smart C, Valagussa P, Viale G, Gianni L (2020) Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial. Ann Oncol 31:S1142\u2013S215. https:\/\/doi.org\/10.1016\/annonc\/annonc325","journal-title":"Ann Oncol"},{"issue":"9","key":"6867_CR23","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O\u2019Shaughnessy J (2020) Pembrolizumab for early triple-negative. Breast Cancer 382(9):810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"Breast Cancer"},{"issue":"10257","key":"6867_CR24","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/s0140-6736(20)31953-x","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N (2020) Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet (London, England) 396(10257):1090\u20131100. https:\/\/doi.org\/10.1016\/s0140-6736(20)31953-x","journal-title":"Lancet (London, England)"},{"key":"6867_CR25","doi-asserted-by":"publisher","first-page":"175883592098563","DOI":"10.1177\/1758835920985632","volume":"13","author":"A Rocca","year":"2021","unstructured":"Rocca A, Cortesi P, Cortesi L, Gianni L, Matteucci F, Fantini L, Maestri A, Giunchi DC, Cavanna L, Ciani R, Falcini F, Bagni A, Meldoli E, Dall\u2019Agata M, Volpi R, Andreis D, Nanni O, Curcio A, Lucchi L, Amadori D, Fedeli A (2021) Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer. Ther adv med oncol 13:1758835920985632. https:\/\/doi.org\/10.1177\/1758835920985632","journal-title":"Ther adv med oncol"},{"key":"6867_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.632357","author":"G Shen","year":"2021","unstructured":"Shen G, Zhao F, Huo X, Ren D, Du F, Zheng F, Zhao J (2021) Meta-analysis of HER2-enriched subtype predicting the pathological complete response within HER2-positive breast cancer in patients who received neoadjuvant treatment. Front oncol. https:\/\/doi.org\/10.3389\/fonc.2021.632357","journal-title":"Front oncol"},{"issue":"Suppl 6","key":"6867_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ajco.13655","volume":"17","author":"J Chen","year":"2021","unstructured":"Chen J, Colosimo M, Lim E (2021) The management of HER2-positive early breast cancer: current and future therapies. Asia-Pacific J clin oncol 17(Suppl 6):3\u201312. https:\/\/doi.org\/10.1111\/ajco.13655","journal-title":"Asia-Pacific J clin oncol"},{"issue":"7\u20138","key":"6867_CR28","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.diii.2014.06.006","volume":"95","author":"I Thomassin-Naggara","year":"2014","unstructured":"Thomassin-Naggara I, Tardivon A, Chopier J (2014) Standardized diagnosis and reporting of breast cancer. Diagn interv imagin 95(7\u20138):759\u201366. https:\/\/doi.org\/10.1016\/j.diii.2014.06.006","journal-title":"Diagn interv imagin"},{"key":"6867_CR29","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.2147\/dddt.S253961","volume":"14","author":"H Wang","year":"2020","unstructured":"Wang H, Mao X (2020) Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer. Drug des, dev ther 14:2423\u20132433. https:\/\/doi.org\/10.2147\/dddt.S253961","journal-title":"Drug des, dev ther"},{"issue":"1","key":"6867_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13058-018-1091-y","volume":"21","author":"SP Gampenrieder","year":"2019","unstructured":"Gampenrieder SP, Peer A, Weismann C, Meissnitzer M, Rinnerthaler G, Webhofer J, Westphal T, Riedmann M, Meissnitzer T, Egger H, Klaassen Federspiel F, Reitsamer R, Hauser-Kronberger C, Stering K, Hergan K, Mlineritsch B, Greil R (2019) Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). Breast Cancer Res 21(1):19. https:\/\/doi.org\/10.1186\/s13058-018-1091-y","journal-title":"Breast Cancer Res"},{"issue":"1","key":"6867_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.21037\/qims.2019.11.16","volume":"10","author":"X Zhang","year":"2020","unstructured":"Zhang X, Wang D, Liu Z, Wang Z, Li Q, Xu H, Zhang B, Liu T, Jin F (2020) The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer. Quant Imaging Med Surg 10(1):197\u2013210. https:\/\/doi.org\/10.21037\/qims.2019.11.16","journal-title":"Quant Imaging Med Surg"},{"issue":"1","key":"6867_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41523-022-00475-1","volume":"8","author":"LM Janssen","year":"2022","unstructured":"Janssen LM, den Dekker BM, Gilhuijs KGA, van Diest PJ, van der Wall E, Elias SG (2022) MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis. NPJ Breast Cancer 8(1):107. https:\/\/doi.org\/10.1038\/s41523-022-00475-1","journal-title":"NPJ Breast Cancer"},{"issue":"14","key":"6867_CR33","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.ejca.2011.06.014","volume":"47","author":"X Kong","year":"2011","unstructured":"Kong X, Moran MS, Zhang N, Haffty B, Yang Q (2011) Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer 47(14):2084\u20132090. https:\/\/doi.org\/10.1016\/j.ejca.2011.06.014","journal-title":"Eur J Cancer"},{"key":"6867_CR34","unstructured":"Research CfDEa. Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval, 2020."},{"key":"6867_CR35","doi-asserted-by":"publisher","first-page":"117822342211035","DOI":"10.1177\/11782234221103504","volume":"16","author":"R Browne","year":"2022","unstructured":"Browne R, McAnena P, O\u2019Halloran N, Moloney BM, Crilly E, Kerin MJ, Lowery AJ (2022) Preoperative breast magnetic resonance imaging as a predictor of response to neoadjuvant chemotherapy. Breast Cancer: Basic Clin Res 16:11782234221103504. https:\/\/doi.org\/10.1177\/11782234221103504","journal-title":"Breast Cancer: Basic Clin Res"},{"issue":"9","key":"6867_CR36","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2217\/nnm.13.118","volume":"8","author":"PP Deshpande","year":"2013","unstructured":"Deshpande PP, Biswas S, Torchilin VP (2013) Current trends in the use of liposomes for tumor targeting. Nanomedicine (London, England) 8(9):1509\u201328. https:\/\/doi.org\/10.2217\/nnm.13.118","journal-title":"Nanomedicine (London, England)"},{"issue":"3","key":"6867_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","volume":"63","author":"V Torchilin","year":"2011","unstructured":"Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Adv drug deliv rev 63(3):131\u20135. https:\/\/doi.org\/10.1016\/j.addr.2010.03.011","journal-title":"Adv drug deliv rev"},{"issue":"1","key":"6867_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","volume":"65","author":"H Maeda","year":"2013","unstructured":"Maeda H, Nakamura H, Fang J (2013) The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv drug deliv rev 65(1):71\u20139. https:\/\/doi.org\/10.1016\/j.addr.2012.10.002","journal-title":"Adv drug deliv rev"},{"key":"6867_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00211","author":"S Azzi","year":"2013","unstructured":"Azzi S, Hebda JK, Gavard J (2013) Vascular permeability and drug delivery in cancers. Front oncol. https:\/\/doi.org\/10.3389\/fonc.2013.00211","journal-title":"Front oncol"},{"key":"6867_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.645026","author":"MJ Gil-Gil","year":"2021","unstructured":"Gil-Gil MJ, Bellet M, Bergamino M, Morales S, Barnadas A, Manso L, Saura C, Fern\u00e1ndez-Ortega A, Garcia-Martinez E, Martinez-Ja\u00f1ez N, Mel\u00e9 M, Villagrasa P, Celiz P, Perez Martin X, Ciruelos E, Pernas S (2021) Long-term cardiac safety and survival outcomes of neoadjuvant pegylated liposomal doxorubicin in elderly patients or prone to cardiotoxicity and triple negative breast cancer final results of the multicentre phase II CAPRICE study. Front oncol. https:\/\/doi.org\/10.3389\/fonc.2021.645026","journal-title":"Front oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06867-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-06867-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-06867-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T02:04:18Z","timestamp":1682733858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-06867-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,4]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["6867"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-06867-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,4]]},"assertion":[{"value":"30 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"The study protocol was approved by the institutional review board of six hospitals (NCKUH, KMUH, CCH, TCH, VGH-TC and TMUH; IRB number: A-ER-110\u2013177, E(I)-20210297, HP220008, REC110-61, CE21429A and N202112074).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}